ALTAVANT SCIENCES PRESENTS DATA SHOWING POTENTIAL FOR COMBINATION OF RODATRISTAT ETHYL AND AMBRISENTAN IN MODEL OF PULMONARY ARTERIAL HYPERTENSION

Rhea-AI Summary

Altavant Sciences announced its presentation of preclinical study results at ATS 2022 in San Francisco, showcasing rodatristat ethyl both as a monotherapy and in combination with ambrisentan for treating pulmonary arterial hypertension (PAH). The study demonstrated promising outcomes in reversing vascular occlusions and regulating mean pulmonary arterial pressure (mPAP). The presentation is scheduled for May 17, 2022, highlighting the therapeutic potential of rodatristat ethyl, which targets serotonin production, a contributor to PAH pathology.

Positive

• Presentation of promising preclinical results for rodatristat ethyl at a major conference (ATS 2022).
• The combination therapy showed potential to reverse vascular occlusions and regulate mean pulmonary arterial pressure (mPAP).
• Rodatristat ethyl targets serotonin production, addressing a key pathological factor in PAH.

Negative

• None.

CARY, N.C. and BASEL, Switzerland, May 6, 2022 /PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced today that the company is presenting results from a preclinical study comparing rodatristat ethyl as a monotherapy and in combination with the type A endothelin receptor antagonist, ambrisentan, in an animal model of pulmonary arterial hypertension (PAH). Results describing changes in post-hypoxia occlusions as well as mean pulmonary arterial pressure (mPAP) with each treatment regimen will be presented in a poster at ATS 2022 being held in San Francisco, CA, May 13-18, 2022.

Presentation Details

Title:	P943 - Rodatristat Ethyl Monotherapy and Combination with Ambrisentan Reverses Incidence of Vascular Occlusions to Baseline Normoxic Levels in the Rat SUGEN-Hypoxia Model of Pulmonary Arterial Hypertension
Session:	Session C56 – Preclinical Models of Pulmonary Hypertension
Date/time:	May 17, 2022, 11:15 - 1:15 p.m. Pacific Time
Location:	San Francisco Marriott Marquis

About Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by vasoconstriction, cellular proliferation, and remodeling in the small pulmonary arteries. These changes lead to high pulmonary arterial pressure, right heart strain, and ultimately, right heart failure and death. Although there are approved treatments used for PAH, they mainly help alleviate symptoms, primarily via vasodilation, and none reverse the disease process. Long-term survival rates for PAH are poor, with less than 40 percent survival at five years for high-risk patients.

About Rodatristat Ethyl
Rodatristat ethyl is a tryptophan hydroxylase (TPH) inhibitor designed to reduce the body's peripheral production of serotonin. A significant body of scientific evidence supports dysregulated peripheral serotonin production as a trigger of aberrant proliferation and constriction of the smooth muscle cells in the wall of the pulmonary arteries, causing them to restrict blood flow in patients with pulmonary arterial hypertension (PAH). By lowering circulating serotonin levels, it is believed that rodatristat ethyl may halt or reverse the pathology of diseases that are driven by excessive serotonin production, such as PAH. Altavant is currently testing this mechanism of action in ELEVATE 2, a proof-of-concept Phase 2 study of rodatristat ethyl in patients with PAH. 

About Altavant Sciences
Altavant Sciences is a clinical-stage biopharmaceutical company focused on elevating patient-centric drug development in rare respiratory diseases. Altavant is currently developing two pipeline candidates: rodatristat ethyl and ALTA-2530. Rodatristat ethyl is a tryptophan hydroxylase (TPH) inhibitor in Phase 2 development for patients with pulmonary arterial hypertension. By reducing serotonin production via TPH inhibition rodatristat ethyl may play a role in halting or reversing the vascular remodeling associated with PAH, offering a novel treatment option for patients living with this disease. ALTA-2530 is an inhaled interleukin-1 receptor antagonist under development for bronchiolitis obliterans syndrome (BOS), a life-threatening form of chronic lung allograft dysfunction (CLAD) that may present following lung transplantation. ALTA-2530's unique mechanism of action may offer a novel treatment option for patients who suffer from BOS, a disease for which there are currently no approved therapies.

Altavant is a wholly owned subsidiary of Sumitovant Biopharma Ltd. For more information, please visit https://altavant.com. 

About Sumitovant Biopharma Ltd.
Sumitovant is a global biopharmaceutical company leveraging data-driven insights to rapidly accelerate development of new potential therapies. Through our unique portfolio of companies—wholly owned Urovant, Enzyvant, Spirovant, Altavant, plus majority-owned Myovant (NYSE: MYOV)—and use of embedded computational technology platforms to generate business and scientific insights, Sumitovant has supported the development of FDA-approved products and advanced a promising pipeline of early-through late-stage investigational assets for other serious conditions. Sumitovant is a wholly owned subsidiary of Sumitomo Pharma. For more information, please visit our website at sumitovant.com or follow us on LinkedIn.

Forward-Looking Statements
This press release contains "forward-looking statements" concerning the development and commercialization of Altavant's products, the company's business development efforts and its expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Altavant undertakes no obligation to update any forward-looking statements for any reason.

View original content to download multimedia:https://www.prnewswire.com/news-releases/altavant-sciences-presents-data-showing-potential-for-combination-of-rodatristat-ethyl-and-ambrisentan-in-model-of-pulmonary-arterial-hypertension-301541434.html

SOURCE Altavant Sciences

FAQ

What were the results of Altavant Sciences' preclinical study on rodatristat ethyl presented at ATS 2022?

Altavant Sciences presented positive results showing that rodatristat ethyl, alone and in combination with ambrisentan, could reverse vascular occlusions and regulate mean pulmonary arterial pressure in a model of pulmonary arterial hypertension.

When is the Altavant Sciences presentation on rodatristat ethyl at ATS 2022?

The presentation is scheduled for May 17, 2022, from 11:15 AM to 1:15 PM Pacific Time.

What is the focus of Altavant Sciences in drug development?

Altavant Sciences focuses on patient-centric drug development in rare respiratory diseases, specifically therapies for pulmonary arterial hypertension.

What is rodatristat ethyl and its significance in PAH treatment?

Rodatristat ethyl is a tryptophan hydroxylase inhibitor designed to decrease serotonin production, which is implicated in the pathology of pulmonary arterial hypertension.

What is the potential impact of rodatristat ethyl on pulmonary arterial hypertension?

By lowering circulating serotonin levels, rodatristat ethyl may halt or reverse the vascular remodeling associated with pulmonary arterial hypertension, offering a novel therapeutic option.